Every year, on 28 July, World Hepatitis Day brings the world together to focus on the theme of raising awareness about the global burden of viral hepatitis (inflammation of the liver), and to advocate for real change. World Hepatitis Day…
In early 2016, the EASL Governing Board initiated a new format for its Schools of Hepatology. In September of the same year, the first pilot of this new format was executed successfully and received overwhelmingly positive feedback from participants. The EASL Schools of Hepatology have been running according to this successful structure for…
An Annual Report with a difference, for a year like none other
ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019…
We would like to thank every single participant who took part in this year's ILC, held 23–26 June 2021. The event brought together almost 6,500 delegates from over 100 countries, who took part in 155 sessions, listened to 566 presentations…
For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to treat NAFLD Friday 25 June 2021 (Geneva, Switzerland)--…
In EASL Studio, we were honoured to keep company with the three 2020 Nobel Laureates, awarded the 2020 Nobel Prize for Physiology and Medicine for their discovery of the hepatitis C virus. They reflected on many thought-provoking topics: the exponential…
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important new developments in hepatitis research at the International…
For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19 vaccine confers low immunity on people with advanced…
